Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street ...

Supernus will make ONAPGO available in the second quarter of 2025. Price Action: SUPN stock is down 14.10% at $34.20 at the last check on Wednesday.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday. Separately, Cantor ...

Piper Sandler analyst David Amsellem maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) yesterday and set a ...

Cantor Fitzgerald downgraded Supernus (NASDAQ:SUPN) to Neutral from Overweight and slashed its price target to $36 from $57 per share, removing SPN-820 from its model after the readout.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Thursday.

Short interest in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) decreased during the last reporting period, falling from 6.02M to 5.74M. This put 15.81% of the company's publicly available shares short.